Cancer-associated phosphopeptide antigen

Cancer-associated phosphopeptide antigens are short peptide fragments derived from proteins that have undergone phosphorylation as a post-translational modification. These peptides are generated due to dysregulated kinase activity in cancer cells and are subsequently presented on the cell surface by MHC class I or II molecules. They constitute a class of tumor-associated antigens that are recognized by specific T cells and can serve as potent targets for immunotherapy. The presentation of these antigens reflects oncogenic signaling pathways involved in uncontrolled cell proliferation and survival. Experimental vaccines and adoptive T cell therapies are being developed that target these peptides to elicit specific immune responses against tumors. Phosphopeptide antigens are not a single gene or protein but are defined by their molecular feature (phosphorylation) and mode of presentation, and their composition depends on the tumor type, MHC alleles, and underlying signaling abnormalities. Current research demonstrates their potential in immunotherapy and cancer surveillance, but heterogeneity and overlap with normal tissue phosphorylation are therapeutic challenges Note: For databases, clinical applications, or drug discovery, specification of the exact phosphopeptide sequence (e.g., from LSP-1 or DOT1L) is required rather than the general grouping term.

Other names

Tumor-associated phosphopeptideMHC phosphopeptidePhosphopeptide neoantigenPhosphorylated tumor antigen

T cell activation via recognition of MHC-bound phosphopeptide antigen (leading to cytolysis of tumor cells) Immune system priming against tumor cells (peptide vaccine)